Sequential use of human-derived medium supplements favours cardiovascular tissue engineering

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 4, 2012, Pages 730-739

  Riem Vis, Paul W ^a   Sluijter, Joost P G ^a   Sarita Soekhradj Soechit, R ^b   van Herwerden, Lex A ^a   Kluin, Jolanda ^a   Bouten, Carlijn V C ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Cardiovascular; Heart valve; Human; Platelet lysate; Serum; Tissue engineering

Indexed keywords

ANIMALIA; BOVINAE;

PRIMER DNA; RNA;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CULTURE MEDIUM; CYTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; NUCLEOTIDE SEQUENCE; TISSUE ENGINEERING; VEIN;

BASE SEQUENCE; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; RNA; TISSUE ENGINEERING; VEINS;

EID: 83655177286     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01351.x     Document Type: Article

References (45)

1. Schoen FJ, Levy RJ. Founders Award, 25th Annual Meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28-May 2, 1999. Tissue heart valves: current challenges and future research perspectives. J Biomed Mater Res. 1999; 47: 439-65.
2. Hoerstrup SP, Cummings Mrcs I, Lachat M, et al. Functional growth in tissueengineered living, vascular grafts: followup at 100 weeks in a large animal model. Circulation. 2006; 114: I159-66.
3. van Geemen D, Driessen-Mol A, Grootzwagers LGM, et al. Variation in ovine and human engineered cardiovascular constructs to predict the outcome of heart valve tissue engineering. Regenerative Medicine. In press.
4. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002; 99: 8932-7.
5. Selvaggi TA, Walker RE, Fleisher TA. Development of antibodies to foetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood. 1997; 89: 776-9.
6. Schmidt D, Joyce EJ, Kao WJ. Foetal bovine serum xenoproteins modulate human monocyte adhesion and protein release on biomaterials in vitro. Acta Biomater. 2011; 7: 515-25.
7. Martin MJ, Muotri A, Gage F, et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med. 2005; 11: 228-32.
8. Capelli C, Domenghini M, Borleri G, et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant. 2007; 40: 785-91.
9. Doucet C, Ernou I, Zhang Y, et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol. 2005; 205: 228-36.
10. Prins HJ, Rozemuller H, Vonk-Griffioen S, et al. Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for foetal bovine serum. Tissue Eng Part A. 2009; 15: 3741-51.
11. Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg. 2006; 118: 147e-59e.
12. Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. Acta Dermatovenerol Alp Panonica Adriat. 2007; 16: 156-65.
13. Weibrich G, Kleis WK, Hafner G, et al. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg. 2002; 30: 97-102.
14. van Geemen D, Riem Vis P, Soekhradj-Soechit S, et al. Decreased mechanical properties of heart valve tissue constructs cultured in platelet lysate as compared to foetal bovine serum. Tissue Eng Part C Methods. 2011; doi: 10.1089/ten.TEC. 2010.0556.
15. Riem Vis PW, Kluin J, Sluijter JP, et al. Environmental regulation of valvulogenesis: implications for tissue engineering. Eur J Cardiothorac Surg. 2011; 39: 8-17.
16. Riem Vis PW, Bouten CV, Sluijter JP, et al. Platelet-lysate as an autologous alternative for foetal bovine serum in cardiovascular tissue engineering. Tissue Eng Part A. 2010; 16: 1317-27.
17. Aikawa E, Whittaker P, Farber M, et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation. 2006; 113: 1344-52.
18. Hoffman-Kim D, Maish MS, Krueger PM, et al. Comparison of three myofibroblast cell sources for the tissue engineering of cardiac valves. Tissue Eng. 2005; 11: 288-301.
19. Mol A, Rutten MC, Driessen NJ, et al. Autologous human tissue-engineered heart valves: prospects for systemic application. Circulation. 2006; 114: I152-8.
20. Schopka S, Schmid FX, Hirt S, et al. Recellularization of biological heart valves with human vascular cells: in vitro hemocompatibility assessment. J Biomed Mater Res B Appl Biomater. 2009; 88: 130-8.
21. Merryman WD, Liao J, Parekh A, et al. Differences in tissue-remodeling potential of aortic and pulmonary heart valve interstitial cells. Tissue Eng. 2007; 13: 2281-9.
22. Mol A, van Lieshout MI, Dam-de Veen CG, et al. Fibrin as a cell carrier in cardiovascular tissue engineering applications. Biomaterials. 2005; 26: 3113-21.
23. Hoerstrup SP, Zund G, Schnell AM, et al. Optimized growth conditions for tissue engineering of human cardiovascular structures. Int J Artif Organs. 2000; 23: 817-23.
24. Krahn KN, Bouten CV, van Tuijl S, et al. Fluorescently labeled collagen binding proteins allow specific visualization of collagen in tissues and live cell culture. Anal Biochem. 2006; 350: 177-85.
25. Boerboom RA, Krahn KN, Megens RT, et al. High resolution imaging of collagen organisation and synthesis using a versatile collagen specific probe. J Struct Biol. 2007; 159: 392-9.
26. Boerboom RA, Rubbens MP, Driessen NJ, et al. Effect of strain magnitude on the tissue properties of engineered cardiovascular constructs. Ann Biomed Eng. 2008; 36: 244-53.
27. Foolen J, van Donkelaar C, Nowlan N, et al. Collagen orientation in periosteum and perichondrium is aligned with preferential directions of tissue growth. J Orthop Res. 2008; 26: 1263-8.
28. Rubbens MP, Driessen-Mol A, Boerboom RA, et al. Quantification of the temporal evolution of collagen orientation in mechanically conditioned engineered cardiovascular tissues. Ann Biomed Eng. 2009; 37: 1263-72.
29. Chen J, Lee SK, Abd-Elgaliel WR, et al. Assessment of cardiovascular fibrosis using novel fluorescent probes. PLoS One. 2011; 6: e19097.
30. Megens RT, Oude Egbrink MG, Cleutjens JP, et al. Imaging collagen in intact viable healthy and atherosclerotic arteries using fluorescently labeled CNA35 and two-photon laser scanning microscopy. Mol Imaging. 2007; 6: 247-60.
31. Megens RTA, oude Egbrink MGA, Merkx M, et al. Two-photon microscopy on vital carotid arteries: imaging the relationship between collagen and inflammatory cells in atherosclerotic plaques. J Biomed Opt. 2008; 13: 044022; doi: 10.1117/1.2965542.
32. Mol A. Functional tissue engineering of human heart valve leaflets. Eindhoven: Technical University Eindhoven; 2005.
33. Mazlyzam AL, Aminuddin BS, Saim L, et al. Human serum is an advantageous supplement for human dermal fibroblast expansion: clinical implications for tissue engineering of skin. Arch Med Res. 2008; 39: 743-52.
34. Kurita M, Aiba-Kojima E, Shigeura T, et al. Differential effects of three preparations of human serum on expansion of various types of human cells. Plast Reconstr Surg. 2008; 122: 438-48.
35. Alexander TH, Sage AB, Chen AC, et al. Insulin-like growth factor-I and growth differentiation factor-5 promote the formation of tissue-engineered human nasal septal cartilage. Tissue Eng Part C Methods. 2010; 16: 1213-21.
36. Ang LP, Tan DT, Seah CJ, et al. The use of human serum in supporting the in vitro and in vivo proliferation of human conjunctival epithelial cells. Br J Ophthalmol. 2005; 89: 748-52.
37. Crowley ST, Dempsey EC, Horwitz KB, et al. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation. 1994; 90: 1908-18.
38. Felka T, Schafer R, De Zwart P, et al. Animal serum-free expansion and differentiation of human mesenchymal stromal cells. Cytotherapy. 2010; 12: 143-53.
39. Kuznetsov SA, Mankani MH, Robey PG. Effect of serum on human bone marrow stromal cells: ex vivo expansion and in vivo bone formation. Transplantation. 2000; 70: 1780-7.
40. Poloni A, Maurizi G, Rosini V, et al. Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow. Cytotherapy. 2009; 11: 153-62.
41. Pytlik R, Stehlik D, Soukup T, et al. The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering. Biomaterials. 2009; 30: 3415-27.
42. Schallmoser K, Bartmann C, Rohde E, et al. Human platelet lysate can replace foetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion. 2007; 47: 1436-46.
43. Taylor PM. Biological matrices and bionanotechnology. Philos Trans R Soc Lond B Biol Sci. 2007; 362: 1313-20.
44. Johansson BM, Wiles MV. Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development. Mol Cell Biol. 1995; 15: 141-51.
45. Gottlieb D, Kunal T, Emani S, et al. In vivo monitoring of function of autologous engineered pulmonary valve. J Thorac Cardiovasc Surg. 2010; 139: 723-31.